Serum from uterine and ovarian cancer patients inhibited growth of RCAS1 putative receptor expressing K562 cells, and this suppressive effect could be partially negated after immunoprecipitation to remove RCAS1 [19, 44]. This evidence concerns the gene EBAG9 and ovarian cancer.